Physician profile
Felix Chu
NPI 1609945807
$2,885.90
in general payments reported to CMS, 2019-2025
14 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $109 · 2021: $289 · 2022: $638 · 2023: $366 · 2024: $397 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $658.87 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $539.61 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $315.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $290.76 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $241.92 | 2019-2022 | |
| Abbott Laboratories | $236.72 | 2023-2024 | Aveir |
| Boston Scientific Corporation | $129.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.51 | 2019-2022 | |
| Pfizer INC. | $80.13 | 2020-2025 | |
| Lilly USA, LLC | $71.13 | 2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $46.90 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $25.67 | 2024 | |
| Novo Nordisk INC | $23.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.